We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Criticism Leads FDA to Withdraw Final cGMP Rule Exempting Phase I Studies
Criticism Leads FDA to Withdraw Final cGMP Rule Exempting Phase I Studies
May 8, 2006
The FDA is withdrawing its direct final rule exempting most investigational drugs from complying with current Good Manufacturing Practices (cGMP) amid criticism of the proposal from a variety of stakeholders.